The Broad-Spectrum Antiviral Potential of the Amphibian Peptide AR-23.

Annalisa Chianese, Carla Zannella, Alessandra Monti, Anna De Filippis, Nunzianna Doti, Gianluigi Franci, Massimiliano Galdiero
Author Information
  1. Annalisa Chianese: Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. ORCID
  2. Carla Zannella: Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. ORCID
  3. Alessandra Monti: Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR), 80134 Naples, Italy.
  4. Anna De Filippis: Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. ORCID
  5. Nunzianna Doti: Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR), 80134 Naples, Italy.
  6. Gianluigi Franci: Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy. ORCID
  7. Massimiliano Galdiero: Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. ORCID

Abstract

Viral infections represent a serious threat to the world population and are becoming more frequent. The search and identification of broad-spectrum antiviral molecules is necessary to ensure new therapeutic options, since there is a limited availability of effective antiviral drugs able to eradicate viral infections, and consequently due to the increase of strains that are resistant to the most used drugs. Recently, several studies on antimicrobial peptides identified them as promising antiviral agents. In detail, amphibian skin secretions serve as a rich source of natural antimicrobial peptides. Their antibacterial and antifungal activities have been widely reported, but their exploitation as potential antiviral agents have yet to be fully investigated. In the present study, the antiviral activity of the peptide derived from the secretion of , named AR-23, was evaluated against both DNA and RNA viruses, with or without envelope. Different assays were performed to identify in which step of the infectious cycle the peptide could act. AR-23 exhibited a greater inhibitory activity in the early stages of infection against both DNA (HSV-1) and RNA (MeV, HPIV-2, HCoV-229E, and SARS-CoV-2) enveloped viruses and, on the contrary, it was inactive against naked viruses (PV-1). Altogether, the results indicated AR-23 as a peptide with potential therapeutic effects against a wide variety of human viruses.

Keywords

References

  1. Antivir Chem Chemother. 2001 Jul;12(4):241-50 [PMID: 11771733]
  2. Peptides. 2011 Jul;32(7):1518-25 [PMID: 21620914]
  3. Biochem Biophys Res Commun. 2003 Jun 27;306(2):496-500 [PMID: 12804591]
  4. Int J Antimicrob Agents. 2004 Apr;23(4):382-9 [PMID: 15081088]
  5. J Virol. 2000 Apr;74(8):3929-31 [PMID: 10729171]
  6. J Chemother. 2016 Apr;28(2):95-103 [PMID: 25801062]
  7. Peptides. 2009 May;30(5):1007-20 [PMID: 19428780]
  8. Front Cell Infect Microbiol. 2021 Jul 30;11:700502 [PMID: 34395311]
  9. Virology. 1993 Oct;196(2):548-56 [PMID: 8396802]
  10. Pharmaceutics. 2021 Dec 08;13(12): [PMID: 34959400]
  11. Eur J Clin Microbiol Infect Dis. 2020 Jan;39(1):5-17 [PMID: 31422545]
  12. J Vis Exp. 2015 Oct 29;(105):e53124 [PMID: 26555014]
  13. Semin Respir Crit Care Med. 2016 Aug;37(4):538-54 [PMID: 27486735]
  14. Antimicrob Agents Chemother. 2018 Apr 26;62(5): [PMID: 29483113]
  15. Sci Rep. 2016 Jun 08;6:27394 [PMID: 27271216]
  16. Cancer Res. 1992 Jul 1;52(13):3534-8 [PMID: 1319823]
  17. Int J Mol Sci. 2021 Jun 17;22(12): [PMID: 34204295]
  18. Microb Pathog. 2018 Jun;119:72-80 [PMID: 29626660]
  19. J Vis Exp. 2013 Dec 03;(82):50833 [PMID: 24326926]
  20. Dev Comp Immunol. 1999 Jun-Jul;23(4-5):329-44 [PMID: 10426426]
  21. Monatsschr Kinderheilkd. 1986 Oct;134(10):710-5 [PMID: 2948113]
  22. Eur Urol. 2006 Jul;50(1):141-7 [PMID: 16476519]
  23. Int J Antimicrob Agents. 2020 Mar;55(3):105924 [PMID: 32081636]
  24. Int J Mol Sci. 2018 Oct 05;19(10): [PMID: 30301180]
  25. J Cancer. 2019 Jan 1;10(2):430-440 [PMID: 30719137]
  26. Mol Med Rep. 2015 Nov;12(5):6483-90 [PMID: 26330195]
  27. Drugs Today (Barc). 2004 Mar;40(3):259-69 [PMID: 15148534]
  28. J Virol. 2005 Sep;79(18):11598-606 [PMID: 16140737]
  29. Viruses. 2016 Jul 28;8(8): [PMID: 27483301]
  30. FASEB J. 2021 Feb;35(2):e21358 [PMID: 33538061]
  31. J Virol. 2003 Apr;77(8):4888-98 [PMID: 12663795]
  32. Clin Exp Pharmacol Physiol. 2006 Jul;33(7):612-6 [PMID: 16789928]
  33. Nat Prod Res. 2021 Feb;35(4):633-636 [PMID: 30908090]
  34. Pharmaceuticals (Basel). 2014 Jan 15;7(1):58-77 [PMID: 24434793]
  35. FEBS Lett. 1992 Sep 14;309(3):235-41 [PMID: 1516693]
  36. J Microbiol. 2016 Dec;54(12):853-866 [PMID: 27888461]
  37. Front Bioeng Biotechnol. 2020 Sep 28;8:569967 [PMID: 33117781]
  38. Int J Antimicrob Agents. 2007 Mar;29(3):317-21 [PMID: 17196372]
  39. J Virol. 2017 Nov 14;91(23): [PMID: 28904193]
  40. Ann Pharmacother. 2003 Oct;37(10):1448-56 [PMID: 14519027]
  41. Int J Oral Sci. 2016 Mar 30;8(1):1-6 [PMID: 27025259]
  42. Biopolymers. 2003;71(1):28-48 [PMID: 12712499]
  43. Phytochemistry. 2018 Oct;154:94-105 [PMID: 30031244]
  44. Nature. 2002 Jan 24;415(6870):389-95 [PMID: 11807545]
  45. Peptides. 2018 Apr;102:38-46 [PMID: 29486214]
  46. Microorganisms. 2021 Jul 21;9(8): [PMID: 34442628]
  47. Int J Microbiol. 2019 Jan 15;2019:4012394 [PMID: 30766602]
  48. Front Pharmacol. 2019 Nov 26;10:1421 [PMID: 31849670]
  49. Viruses. 2019 Jan 18;11(1): [PMID: 30669255]
  50. Nat Commun. 2021 Mar 29;12(1):1936 [PMID: 33782395]

MeSH Term

Amphibian Proteins
Animals
Antimicrobial Cationic Peptides
Antimicrobial Peptides
Antiviral Agents
Cell Survival
Chlorocebus aethiops
DNA Viruses
RNA Viruses
Ranidae
SARS-CoV-2
Vero Cells
Viral Envelope
Viral Plaque Assay
Virus Diseases

Chemicals

AR-23 peptide, Rana fagoi
Amphibian Proteins
Antimicrobial Cationic Peptides
Antimicrobial Peptides
Antiviral Agents

Word Cloud

Created with Highcharts 10.0.0antiviralAR-23virusesdrugsantimicrobialpeptidespeptideinfectionstherapeuticagentspotentialactivityDNARNAHSV-1SARS-CoV-2Viralrepresentseriousthreatworldpopulationbecomingfrequentsearchidentificationbroad-spectrummoleculesnecessaryensurenewoptionssincelimitedavailabilityeffectiveableeradicateviralconsequentlydueincreasestrainsresistantusedRecentlyseveralstudiesidentifiedpromisingdetailamphibianskinsecretionsserverichsourcenaturalantibacterialantifungalactivitieswidelyreportedexploitationyetfullyinvestigatedpresentstudyderivedsecretionnamedevaluatedwithoutenvelopeDifferentassaysperformedidentifystepinfectiouscycleactexhibitedgreaterinhibitoryearlystagesinfectionMeVHPIV-2HCoV-229EenvelopedcontraryinactivenakedPV-1AltogetherresultsindicatedeffectswidevarietyhumanBroad-SpectrumAntiviralPotentialAmphibianPeptidetherapycoronavirus

Similar Articles

Cited By